Clinical Trials
6 trialsNCT02437136 2025-03-20
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT03765229 2024-01-10
An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02697630 2023-12-08
PEMDAC
Vastra Gotaland Region
Phase 2 Completed
NCT00185302 2015-12-14
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
Bayer
Phase 2 Completed
NCT00098891 2013-01-24
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00020579 2012-03-15
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed